

# Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

Last Update: Sep 15, 2025

A Two-stage Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

ClinicalTrials.gov Identifier:

[NCT05948943](#)

Novartis Reference Number: CBYL719P12201

[See if you Pre-qualify](#)

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

## Study Description

The main purpose of this study in participants with PIK3CA-mutated LyM is to assess the change in radiological response and symptom severity upon treatment with alpelisib film-coated tablets (FCT) as compared to placebo. This is a phase II/III multi-center study with two stages:

\* Stage 1 is designed to select the dose(s) for the confirmatory phase (DSCP) for alpelisib in Stage 2 and will comprise a 24-week open-label core phase in adult ( $\geq 18$  years of age) and pediatric participants (6-17 years of age) with PIK3CA-mutated LyM, followed by an extension. After eligibility has been confirmed at screening, participants will be randomized in a 1:1 ratio to the different alpelisib doses according to their age. Depending on the results at the end of Stage 1 core phase, the Stage 2 will be opened to adult and/or pediatric participants or the study may be stopped.

\* Stage 2 is designed to confirm the efficacy and assess safety of alpelisib at the DSCP in participants with PIK3CA-mutated LyM and will comprise a 24-week randomized, double blind, placebo-controlled confirmatory phase in adult ( $\geq 18$  years of age) and pediatric participants 6-17 years of age followed by an open-label extension. After eligibility has been confirmed at screening participants will be randomized in a 2:1 ratio to alpelisib or placebo.

Additionally, in parallel, Stage 2 will include a 24-week open-label core phase in pediatric participants 0-5 years of age followed by an extension, if pediatric participants will be enrolling in Stage 2.

Based on the results of the 24-week open-label core phase of Stage 1, the dose(s) for Stage 2 will be selected by Novartis in consultation with the Steering Committee (SC). During the 24-week randomized, double blind, placebo-controlled core phase of Stage 2, an Independent Data Monitoring Committee (DMC) will conduct periodic safety and efficacy reviews to assess the risk benefit profile of the treatment.

Condition

Lymphatic Malformations

Phase  
Phase2, Phase3  
Overall Status  
Recruiting  
Number of Participants  
232  
Start Date  
Nov 24, 2023  
Completion Date  
May 02, 2033  
Gender  
All  
Age(s)  
0 Years - 100 Years (Child, Adult, Older Adult)

## Interventions

Drug

### Alpelisib

In Stage 1: adult participants ( $\geq 18$  years of age) will receive dose 1 or dose 2 of alpelisib; pediatric participants (6-17 years of age) will receive dose 2 or dose 3 of alpelisib. In Stage 2: Adult participants will receive alpelisib at the dose selected for confirmatory phase in adult participants; pediatric participants (6-17 years of age) will receive alpelisib at the dose selected for confirmatory phase in pediatric participants; and pediatric participants of 0-5 years of age will receive dose 3 of alpelisib

Drug

### Placebo

In Stage 2, participants will receive matching placebo for 24 weeks of the study

## Eligibility Criteria

Key inclusion criteria:

1. Signed informed consent and assent (when applicable) from the participant, parent, legal authorized representative or guardian.
2. Participant must be willing to remain at the clinical site as required by the protocol and be willing to adhere to study restrictions and examination schedules.
3. Participant has a physician confirmed and documented diagnosis of a symptomatic LyM at the time of informed consent (Note: the physician must confirm that the LyM cannot be included under the PROS diagnostic criteria).
4. Participant is not considered as a candidate for or is not willing to receive non-drug therapies including but not limited to sclerotherapy, embolization, and surgery until the completion of Week 24 in Stage 1 and 2.
5. Participant has evidence of a somatic mutation(s) in the PIK3CA gene prior to randomization.
6. Participant has at least one measurable LyM lesion confirmed by BIRC assessment prior to randomization.
7. Participants must be able to ingest study drug (either in tablet form or as a drinkable suspension \[Groups 1 to 4\] or granules or as an oral suspension \[Group 5\]) as assessed within 7 days before study treatment start.

Drug administration via feeding tubes is allowed.

Key exclusion criteria:

1. Participant has a physician-confirmed and documented diagnosis of PROS at the time of informed consent.
2. Participant has a physician-confirmed and documented diagnosis of a Central Conducting Lymphatic Anomaly, General Lymphatic Anomaly, Gorham-Stout disease, Kaposiform lymphangiomatosis at the time of informed consent.
3. Participant has a known history of Stevens-Johnson syndrome, erythema multiforme, or toxic epidermal necrolysis at the time of informed consent.
4. Participant has an established diagnosis of type I diabetes mellitus or uncontrolled type II diabetes mellitus at the time of informed consent.
5. Participant had previous treatment with alpelisib and/or any other PI3K inhibitors with treatment duration longer than 2 weeks at the time of informed consent.

Other inclusion/exclusion criteria may apply

## **Australia**

### **Novartis Investigative Site**

Recruiting

Brisbane,Queensland,4101,Australia

### **Novartis Investigative Site**

Recruiting

Darlinghurst,2010,Australia

### **Novartis Investigative Site**

Recruiting

Randwick,New South Wales,2031,Australia

## **Belgium**

### **Novartis Investigative Site**

Recruiting

Bruxelles,1200,Belgium

## **France**

### **Novartis Investigative Site**

Recruiting

Lille,59000,France

### **Novartis Investigative Site**

Recruiting

Marseille,13885,France

**Novartis Investigative Site**

Recruiting

Montpellier,34295,France

**Novartis Investigative Site**

Recruiting

Dijon,21034,France

**Novartis Investigative Site**

Recruiting

Bordeaux Cedex,33076,France

**Novartis Investigative Site**

Recruiting

Paris,75010,France

**Novartis Investigative Site**

Recruiting

Bron Cedex,69677,France

**Novartis Investigative Site**

Recruiting

Tours,37044,France

**Novartis Investigative Site**

Recruiting

Toulouse,31400,France

**Novartis Investigative Site**

Recruiting

Caen,14033,France

**Germany**

**Novartis Investigative Site**

Recruiting

Cologne,50937,Germany

**Novartis Investigative Site**

Recruiting

Mannheim,Baden Wuerttemberg,68305,Germany

**Novartis Investigative Site**

Recruiting

Leipzig,Sachsen,04103,Germany

**Novartis Investigative Site**

Recruiting

Freiburg,79106,Germany

**Italy****Novartis Investigative Site**

Recruiting

Bologna,BO,40138,Italy

**Novartis Investigative Site**

Recruiting

Milan,MI,20122,Italy

**Novartis Investigative Site**

Recruiting

Roma,RM,00165,Italy

**Novartis Investigative Site**

Recruiting

Roma,RM,00168,Italy

**Novartis Investigative Site**

Recruiting

Napoli,80122,Italy

## **Spain**

### **Novartis Investigative Site**

Recruiting

Madrid,28046,Spain

### **Novartis Investigative Site**

Recruiting

Esplugues de Llobregat,Barcelona,08950,Spain

## **United States**

### **U of TX Health Science Ct**

Recruiting

Houston,Texas,77030,United States

**Alyssa Rice**

Phone: [713-500-6852](tel:713-500-6852)

Email: [alyssa.a.rice@uth.tmc.edu](mailto:alyssa.a.rice@uth.tmc.edu)

**Ionela Iacobas**

**Autumn Atkinson**

**Janaei Phillips**

Phone: [713-500-6852](tel:713-500-6852)

Email: [janaei.phillips@uth.tmc.edu](mailto:janaei.phillips@uth.tmc.edu)

**Cara-Lee Fontaine**

Phone: [713-798-3701](tel:713-798-3701)

Email: [clfontai@texaschildrens.org](mailto:clfontai@texaschildrens.org)

### **Childrens National Medical Center**

Recruiting

Washington D.C.,District of Columbia,20010-2970,United States

**Regine Hyppolite**

Email: [rhyppolite@childrensnational.org](mailto:rhyppolite@childrensnational.org)

Yaser Diab

## **UHO Cleveland Or Ireland Canc Ct**

Recruiting

Cleveland, Ohio, 44106, United States

Antonio Levert

Phone: 216-844-7028

Email: Antonio.Levert@UHhospitals.org

Hayley Sluka

Phone: 216-844-7028

Email: hayley.sluka@uhhospitals.org

Howard Wang

## **Childrens Hospital and Regional Medical Center**

Recruiting

Seattle, Washington, 98105, United States

Maya Gopalan

Phone: 206-526-2100

Email: maya.gopalan@seattlechildrens.org

Jonathan A Perkins

## **UCSF Benioff Children s Hospital**

Recruiting

Oakland, California, 94609, United States

Audrey Hernando

Phone: +1 510 428 3885 8227

Email: Audrey.Hernando@ucsf.edu

Beth Apsel Winger

## **WA Uni School Of Med**

Recruiting

St Louis, Missouri, 63110, United States

Sally Jones

Email: [jones\\_s@wustl.edu](mailto:jones_s@wustl.edu)

Bryan Sisk

Sally Jones

Email: [jones\\_s@wustl.edu](mailto:jones_s@wustl.edu)

Bryan Sisk

## **Cinn Children Hosp Medical Center**

Recruiting

Cincinnati, Ohio, 45229-3039, United States

Kimberly Whittaker

Phone: [513-636-6090](tel:513-636-6090)

Email: [Kimberly.Whittaker@cchmc.org](mailto:Kimberly.Whittaker@cchmc.org)

Adrienne Hammill

Amy Shova

Phone: [513-636-6090](tel:513-636-6090)

Email: [Amy.Shova@cchmc.org](mailto:Amy.Shova@cchmc.org)

## **Lucile Packard Childrens Hosp**

Recruiting

Palo Alto, California, 94304, United States

Joyce Teng

Ramrada Lekwuttikarn

Email: [ramrada1@stanford.edu](mailto:ramrada1@stanford.edu)

## **CHOP Abramson Pediatric Resch Ctr**

Recruiting

Philadelphia, Pennsylvania, 19104, United States

Denise Adams

Lulu Gao

Email: [gaoc@chop.edu](mailto:gaoc@chop.edu)



**Samantha Santos**

Email: [santoss3@chop.edu](mailto:santoss3@chop.edu)

## **Oregon Health Science University**

Recruiting

Portland, Oregon, 97239, United States

**Denae Clohessy**

Email: [clohessy@ohsu.edu](mailto:clohessy@ohsu.edu)

**Melinda Wu**

## **Childrens Hosp Boston Dept of Heme**

Recruiting

Boston, Massachusetts, 02115, United States

**Emma Bell**

Phone: [617-355-7700](tel:617-355-7700)

Email: [emma.bell@childrens.harvard.edu](mailto:emma.bell@childrens.harvard.edu)

**Shruthi Sudhakar**

Phone: [617-355-7700](tel:617-355-7700)

Email: [shruthi.sudhakar@childrens.harvard.edu](mailto:shruthi.sudhakar@childrens.harvard.edu)

**Tishi Shah**

**Yeji Lee**

Phone: [617-355-7700](tel:617-355-7700)

Email: [yeji.lee@childrens.harvard.edu](mailto:yeji.lee@childrens.harvard.edu)

## **Worldwide Contacts**

If the location of your choosing does not feature any contact detail, please reach out using the information below.

### **Novartis Pharmaceuticals**

Phone: [+41613241111](tel:+41613241111)

Email: [novartis.email@novartis.com](mailto:novartis.email@novartis.com)

### **Novartis Pharmaceuticals**

Phone: [1-888-669-6682](tel:1-888-669-6682)

**Source URL:** <https://prod1.novartis.com/clinicaltrials/study/nct05948943>

**List of links present in page**

1. <https://clinicaltrials.gov/ct2/show/NCT05948943>
2. [#trial-eligibility](#)
3. <tel:713-500-6852>
4. <mailto:alyssa.a.rice@uth.tmc.edu>
5. <tel:713-500-6852>
6. <mailto:janaei.phillips@uth.tmc.edu>
7. <tel:713-798-3701>
8. <mailto:clfontai@texaschildrens.org>
9. <mailto:rhyppolite@childrensnational.org>
10. <tel:216-844-7028>
11. <mailto:Antonio.Lever@UHHospitals.org>
12. <tel:216-844-7028>
13. <mailto:hayley.sluka@uhhospitals.org>
14. <tel:206-526-2100>
15. <mailto:maya.gopalan@seattlechildrens.org>
16. [tel:+1 510 428 3885 8227](tel:+151042838858227)
17. <mailto:Audrey.Hernando@ucsf.edu>
18. [mailto:jones\\_s@wustl.edu](mailto:jones_s@wustl.edu)
19. [mailto:jones\\_s@wustl.edu](mailto:jones_s@wustl.edu)
20. <tel:513-636-6090>
21. <mailto:Kimberly.Whittaker@cchmc.org>
22. <tel:513-636-6090>
23. <mailto:Amy.Shova@cchmc.org>
24. <mailto:ramrada1@stanford.edu>
25. <mailto:gaoc@chop.edu>
26. <mailto:santoss3@chop.edu>
27. <mailto:clohessy@ohsu.edu>
28. <tel:617-355-7700>
29. <mailto:emma.bell@childrens.harvard.edu>
30. <tel:617-355-7700>
31. <mailto:shruthi.sudhakar@childrens.harvard.edu>
32. <tel:617-355-7700>
33. <mailto:yeji.lee@childrens.harvard.edu>
34. <tel:+41613241111>
35. <mailto:novartis.email@novartis.com>
36. <tel:1-888-669-6682>
37. <mailto:novartis.email@novartis.com>